Clostridioides difficile spore

Clostridioides difficile spores are dormant, highly resistant structures produced by this Gram-positive, anaerobic, spore-forming bacterium, which is the leading cause of antibiotic-associated diarrhea and a major healthcare-associated infection. These spores feature a multi-layered architecture including a protective exosporium (in some strains), proteinaceous coat, cortex peptidoglycan, and a dehydrated core rich in calcium-dipicolinic acid (Ca-DPA), conferring resistance to heat, antibiotics, disinfectants, and gastric acid, enabling environmental persistence and transmission. Biologically, spores undergo germination triggered by bile acids like taurocholate via receptors such as CspC, followed by cortex hydrolysis by SleC, leading to outgrowth into toxin-producing vegetative cells responsible for CDI pathology. In disease, spores drive initial infection and high recurrence rates (up to 25-30%) after antibiotic treatment, as standard therapies like vancomycin and fidaxomicin kill vegetative cells but spare spores, perpetuating outbreaks especially with hypervirulent strains. Therapeutic targeting focuses on germination inhibitors (e.g., oxadiazoles), sporulation blockers, and spore surface proteins like CdeC or coat components (CotA, BclA family) for vaccines or antibodies to prevent colonization and recurrence, with ongoing developments in phage therapy and decoy receptors.

Other names

C. difficile sporeClostridium difficile spore

Inhibition of spore germination (e.g., oxadiazoles block primary bile acid sensing via CspC), Disruption of spore cortex peptidoglycan (SleC lytic enzyme activation block), Killing vegetative cells post-germination, Reduced sporulation to prevent recurrence